CA2791526A1 - Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient - Google Patents
Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient Download PDFInfo
- Publication number
- CA2791526A1 CA2791526A1 CA2791526A CA2791526A CA2791526A1 CA 2791526 A1 CA2791526 A1 CA 2791526A1 CA 2791526 A CA2791526 A CA 2791526A CA 2791526 A CA2791526 A CA 2791526A CA 2791526 A1 CA2791526 A1 CA 2791526A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- rebamipide
- osteoarthritis
- cartilage
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided is a pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide and a pharmaceutically acceptable carrier. The pharmaceutical composition can be of a form for oral administration, and preferably can have a solid oral formulation taking the form of a tablet or capsule. Also, the pharmaceutical composition can be prepared in a unit dosage form suitable for oral administration in a dose of from 0.5 to 50 mg/kg, and preferably from 0.6 to 6 mg/kg.
Description
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF
OSTEOARTHRITIS CONTAINING REBAMIPIDE AS AN ACTIVE INGREDIENT
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient.
BACKGROUND ART
Osteoarthritis, one of the types of arthritis, is also referred to as degenerative arthritis. It is said that osteoarthritis is an arthritis caused by degenerative changes in the cartilage and adjacent bone in the synovial joints. That is, osteoarthritis is characterized by gradual loss of articular cartilage, combined with thickening of the subchondral bone, bony outgrowths at the joint margins, and nonspecific synovial inflammation. Osteoarthritis is caused by cartilage damages according to aging and/or physical stresses (for example, obesity, trauma, etc.). Therefore, osteoarthritis involves severe pain and/or movement disorder in the weight-bearing joints, such as knee joint and hip joint; and the negligence thereof for long time results in joint malformations.
Typically, osteoarthritis is progressed in the following steps: the cartilage change phase in which edema occurs by the increase of water contents in the cartilage (step 1);
the fibrillation phase in which the cartilage is destructed, thereby resulting in erosion of the cartilage surface, bone exposure, and narrow articular cavity (step 2);
the overall cartilage reduction phase in which, although chondrocytes initiate compensatory cartilage formation, cartilage breakdown occurs faster than cartilage formation (step 3);
the bone malformation phase in which the bone modification results in joint malformations and dysfunctions (step 4); and the changes of articular soft tissue in which the soft tissue become thickened (step 5).
Rheumatoid arthritis, which belongs to a different type of arthritis from osteoarthritis, is a chronic autoimmune disease characterized by inflammation and proliferation of synovial cells; and causes osteoporosis and bone erosion around in the joints, unlike osteoarthritis. Typically, rheumatoid arthritis is progressed in the following steps: inflammation in the synovial membrane spreads to joint capsules, ligaments, tendons, etc (step 1); progressive destruction of joint cartilage leads to narrowing the joint space and destroying tension of both joint capsule and ligament (step 2);
inflammation infiltrates into bone, thereby inducing partial bone erosion (step 3); and functional disability is caused in the joint (step 4). Therefore, rheumatoid arthritis and osteoarthritis are quite different in their etiologies and progressions, and therefore the therapeutic methods thereof are also different.
The treatment of osteoarthritis used in the prior arts includes the use of therapeutic agents, for example acetaminophen, tramadol, nonsteroidal antiinflammatory drugs (NSAIDs), diacerin, glucosamine, etc. Among them, the NSAIDs have been reported to induce side effects in the gastrointestinal tract, such as gastric ulcer, duodenal ulcer, etc. Therefore, when these drugs are applied to a patient Is suffering from osteoarthritis and potential problem of gastrointestinal side effects, a cytoprotective agent (e.g., rebamipide, etc), a H2-receptor antagonist (e.g., cimetidine, ranitidine, etc), and/or a proton pump inhibitor (e.g., omeprazole) are also co-administered.
DETAILED DESCRIPTION OF THE INVENTION
TECHNICAL PROBLEM
The present inventors unexpectedly found, during the treatment of various patients suffering from osteoarthritis in the clinics, that rebamipide per se co-administered for avoiding gastrointestinal side effects has an activity for preventing or treating osteoarthritis. It is very surprising since it has not been reported that rebamipide could be related to improvement and/or therapeutic effect against osteoarthritis.
Therefore, the present invention provides a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient.
TECHNICAL SOLUTION
According to an aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier.
The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide io in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.
ADVANTAGEOUS EFFECTS
It is newly found by the present invention that rebamipide has an activity for is preventing or treating osteoarthritis. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating osteoarthritis, independently or in combination of other therapeutic agent(s) for treating osteoarthritis.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is the results obtained by observing the femurs and tibias isolated from the rats under a microscope at the 7th day after the osteoarthritis induction.
FIG. 2 is the results obtained by histologically analyzing cartilage damages through TRAP, safranin 0, and H&E staining.
FIG. 3 is a graph illustrating the histology grades calculated from the histological analyses.
BEST MODE FOR CARRYING OUT THE INVENTION
As used herein, the term "rebamipide" includes all forms of rebamipide, such as anhydrous form, hydrate form (e.g., hemihyrate form), crystalline forms, etc;
and a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt includes an inorganic ionic salt originated from for example calcium, potassium, sodium, and magnesium; an inorganic acid salt originated from for example hydrochloric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, and sulfuric acid; an organic acid salt originated from for example acetic acid, formic acid, succinic acid, tartaric acid, citric acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, and maleic acid; an sulfonic acid salt originated from for example methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and naphthalenesulfonic acid; an amino acid salt originated from to for example glycine, arginine, and lysine; and an amine salt originated from for example trimethylamine, triethylamine, ammonia, pyridine, and picoline.
The present invention provides a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier.
As described in the Example below, when osteoarthritis was induced in rats by administering monosodium iodoacetate (MIA) known as an osteoarthritis-inducing agent and then rebamipide was orally administered to the rats, the cartilage damages were significantly inhibited (see FIG. 1). As a result of histological analyses, when rebamipide was orally administered, the losses of cartilage and its components were similar to those of the normal rats; and the cartilage destruction and the degradation of its components were favorably changed (see FIG. 2 and FIG. 3). These results show that the rebamipide used as a cytoprotective agent has an excellent activity for treating osteoarthritis.
The pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier, and can be formulated according to conventional methods into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, or aerosols; external dosage forms;
susppository; or sterile injection solution. Preferably, the pharmaceutical composition of the present invention may be a form for oral administration, for example an oral solid dosage form of 3o a tablet or capsule form. For example, the pharmaceutical composition of the present invention may in the form of a commercially marketed rebamipide-containing tablet (for example, "MucostaTM Tablet", Otsuka Pharmaceutical Co., Ltd.). The pharmaceutically acceptable carrier includes lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose 2910, polyethylene glycol 6000, polyvinylpyrrolidone, methyl hydroxybenzoate, propyl hydroxybenzoate, titanium dioxide, talc, magnesium stearate, and mineral oil, but not limited thereto. The pharmaceutical composition may further include a dilluent or an excipient, such as filler, expander, binder, humectant, disintegrant, or surfactant. A
io solid oral formulation includes for example a tablet, a pill, a powder, a granule, or a capsule. Such solid formulations may include at least one excipient selected from, for example, starch, calcium carbonate, sucrose, lactose, and gelatin. In addition, such solid formulations may further include a lubricant, such as magnesium stearate or talc.
Specifically, the pharmaceutical composition of the present invention may be a tablet form comprising rebamipide as an active ingredient; and low-substituted hydroxypropyl cellulose, microcrystalline cellulose, titanium dioxide, hydroxypropyl methylcellulose 2910, polyethylene glycol 6000, hydroxypropyl cellulose, and magnesium stearate as a carrier. A liquid oral formulation includes a suspension, a solution, an emulsion, or syrup. In addition, the liquid oral formulation may include a dilluent such as water, liquid paraffin; a humectant; a sweetening agent; an odorant; or a preservative. A
parenteral formulation includes a sterile aqueous solution, a non-aqueous solution, a suspension, an emulsion, a lyophilized formulation, or a suppository. Non-aqueous solvents or suspending agents includes propylene glycol, polyethylene glycol, vegetable oil such as olive oil, or injectable esters such as ethyl oleate. Bases for suppository may be witepsol, macrogol, Tween 61, cacao butter, Laurin, or glycerogelatine.
In the pharmaceutical composition according to the present invention, a dose of rebamipide may vary depending on patient's state or body weight, seriousness of disease, dosage forms, administration routes, and the period of administration, and can be appropriately determined by a person having ordinary skill in the art. For example, 3o rebamipide may be administered in a dose of 0.1 to 100 mg/kg, preferably 0.5 to 50 mg/kg, more preferably 0.6 to 6 mg/kg, per day. Therefore, the pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.
The administration can be completed once or through several times per day. The pharmaceutical composition of the present invention can be also administered independently or in combination with other therapeutic agent(s) for osteoarthritis such as non-steroidal anti-inflammatory drugs (NSAIDs), etc. When administered as a combination, the therapeutic agent(s) can be administered sequentially or at the same time.
Hereinafter, the present invention will be described more specifically by the 1o following working example. However, the following working example is provided only for illustrations and thus the present invention is not limited to or by it.
Example: Evaluation of therapeutic efficacy of rebamipide on osteoarthritis according to oral administration (1) Test method About 5 week old male Wistar rats were used. Monosodium iodoacetate (MIA) was dissolved in a physiological saline; and then administered to the rats in the dose of 4 mg / 50 pl via the right knee thereof, so as to induce osteoarthritis.
The rats were divided into 3 groups, each having 5 rats. The first group (non-arthritis) was a non-treated group, i.e., a normal control group. The second group (MIA) was an osteoarthritis-induced group through the MIA administration. The rats of the third group (MIA+Rebamipide) were administered with the MIA to induce osteoarthritis; and then orally administered with rebamipide every day for 7 days.
At the 7th day after the MIA induction, the femurs and the tibias were isolated from the rats of each group and then observed under a dissecting microscope.
After H&E staining, the knee joint sites were observed through a low-magnification lens. In the results, the nucleus is shown in blue-violet color and the cytoplasm is shown in pink color. After completion of the stainings, the tissues were observed in detail, dividing two sites, i.e., the upper site of the knee (shown as "F" which is the abbreviation of femurs) and the lower site of the knee (shown as "T" which is the abbreviation of tibias).
OSTEOARTHRITIS CONTAINING REBAMIPIDE AS AN ACTIVE INGREDIENT
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient.
BACKGROUND ART
Osteoarthritis, one of the types of arthritis, is also referred to as degenerative arthritis. It is said that osteoarthritis is an arthritis caused by degenerative changes in the cartilage and adjacent bone in the synovial joints. That is, osteoarthritis is characterized by gradual loss of articular cartilage, combined with thickening of the subchondral bone, bony outgrowths at the joint margins, and nonspecific synovial inflammation. Osteoarthritis is caused by cartilage damages according to aging and/or physical stresses (for example, obesity, trauma, etc.). Therefore, osteoarthritis involves severe pain and/or movement disorder in the weight-bearing joints, such as knee joint and hip joint; and the negligence thereof for long time results in joint malformations.
Typically, osteoarthritis is progressed in the following steps: the cartilage change phase in which edema occurs by the increase of water contents in the cartilage (step 1);
the fibrillation phase in which the cartilage is destructed, thereby resulting in erosion of the cartilage surface, bone exposure, and narrow articular cavity (step 2);
the overall cartilage reduction phase in which, although chondrocytes initiate compensatory cartilage formation, cartilage breakdown occurs faster than cartilage formation (step 3);
the bone malformation phase in which the bone modification results in joint malformations and dysfunctions (step 4); and the changes of articular soft tissue in which the soft tissue become thickened (step 5).
Rheumatoid arthritis, which belongs to a different type of arthritis from osteoarthritis, is a chronic autoimmune disease characterized by inflammation and proliferation of synovial cells; and causes osteoporosis and bone erosion around in the joints, unlike osteoarthritis. Typically, rheumatoid arthritis is progressed in the following steps: inflammation in the synovial membrane spreads to joint capsules, ligaments, tendons, etc (step 1); progressive destruction of joint cartilage leads to narrowing the joint space and destroying tension of both joint capsule and ligament (step 2);
inflammation infiltrates into bone, thereby inducing partial bone erosion (step 3); and functional disability is caused in the joint (step 4). Therefore, rheumatoid arthritis and osteoarthritis are quite different in their etiologies and progressions, and therefore the therapeutic methods thereof are also different.
The treatment of osteoarthritis used in the prior arts includes the use of therapeutic agents, for example acetaminophen, tramadol, nonsteroidal antiinflammatory drugs (NSAIDs), diacerin, glucosamine, etc. Among them, the NSAIDs have been reported to induce side effects in the gastrointestinal tract, such as gastric ulcer, duodenal ulcer, etc. Therefore, when these drugs are applied to a patient Is suffering from osteoarthritis and potential problem of gastrointestinal side effects, a cytoprotective agent (e.g., rebamipide, etc), a H2-receptor antagonist (e.g., cimetidine, ranitidine, etc), and/or a proton pump inhibitor (e.g., omeprazole) are also co-administered.
DETAILED DESCRIPTION OF THE INVENTION
TECHNICAL PROBLEM
The present inventors unexpectedly found, during the treatment of various patients suffering from osteoarthritis in the clinics, that rebamipide per se co-administered for avoiding gastrointestinal side effects has an activity for preventing or treating osteoarthritis. It is very surprising since it has not been reported that rebamipide could be related to improvement and/or therapeutic effect against osteoarthritis.
Therefore, the present invention provides a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient.
TECHNICAL SOLUTION
According to an aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier.
The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide io in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.
ADVANTAGEOUS EFFECTS
It is newly found by the present invention that rebamipide has an activity for is preventing or treating osteoarthritis. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating osteoarthritis, independently or in combination of other therapeutic agent(s) for treating osteoarthritis.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is the results obtained by observing the femurs and tibias isolated from the rats under a microscope at the 7th day after the osteoarthritis induction.
FIG. 2 is the results obtained by histologically analyzing cartilage damages through TRAP, safranin 0, and H&E staining.
FIG. 3 is a graph illustrating the histology grades calculated from the histological analyses.
BEST MODE FOR CARRYING OUT THE INVENTION
As used herein, the term "rebamipide" includes all forms of rebamipide, such as anhydrous form, hydrate form (e.g., hemihyrate form), crystalline forms, etc;
and a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt includes an inorganic ionic salt originated from for example calcium, potassium, sodium, and magnesium; an inorganic acid salt originated from for example hydrochloric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, and sulfuric acid; an organic acid salt originated from for example acetic acid, formic acid, succinic acid, tartaric acid, citric acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, and maleic acid; an sulfonic acid salt originated from for example methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and naphthalenesulfonic acid; an amino acid salt originated from to for example glycine, arginine, and lysine; and an amine salt originated from for example trimethylamine, triethylamine, ammonia, pyridine, and picoline.
The present invention provides a pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier.
As described in the Example below, when osteoarthritis was induced in rats by administering monosodium iodoacetate (MIA) known as an osteoarthritis-inducing agent and then rebamipide was orally administered to the rats, the cartilage damages were significantly inhibited (see FIG. 1). As a result of histological analyses, when rebamipide was orally administered, the losses of cartilage and its components were similar to those of the normal rats; and the cartilage destruction and the degradation of its components were favorably changed (see FIG. 2 and FIG. 3). These results show that the rebamipide used as a cytoprotective agent has an excellent activity for treating osteoarthritis.
The pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier, and can be formulated according to conventional methods into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, or aerosols; external dosage forms;
susppository; or sterile injection solution. Preferably, the pharmaceutical composition of the present invention may be a form for oral administration, for example an oral solid dosage form of 3o a tablet or capsule form. For example, the pharmaceutical composition of the present invention may in the form of a commercially marketed rebamipide-containing tablet (for example, "MucostaTM Tablet", Otsuka Pharmaceutical Co., Ltd.). The pharmaceutically acceptable carrier includes lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose 2910, polyethylene glycol 6000, polyvinylpyrrolidone, methyl hydroxybenzoate, propyl hydroxybenzoate, titanium dioxide, talc, magnesium stearate, and mineral oil, but not limited thereto. The pharmaceutical composition may further include a dilluent or an excipient, such as filler, expander, binder, humectant, disintegrant, or surfactant. A
io solid oral formulation includes for example a tablet, a pill, a powder, a granule, or a capsule. Such solid formulations may include at least one excipient selected from, for example, starch, calcium carbonate, sucrose, lactose, and gelatin. In addition, such solid formulations may further include a lubricant, such as magnesium stearate or talc.
Specifically, the pharmaceutical composition of the present invention may be a tablet form comprising rebamipide as an active ingredient; and low-substituted hydroxypropyl cellulose, microcrystalline cellulose, titanium dioxide, hydroxypropyl methylcellulose 2910, polyethylene glycol 6000, hydroxypropyl cellulose, and magnesium stearate as a carrier. A liquid oral formulation includes a suspension, a solution, an emulsion, or syrup. In addition, the liquid oral formulation may include a dilluent such as water, liquid paraffin; a humectant; a sweetening agent; an odorant; or a preservative. A
parenteral formulation includes a sterile aqueous solution, a non-aqueous solution, a suspension, an emulsion, a lyophilized formulation, or a suppository. Non-aqueous solvents or suspending agents includes propylene glycol, polyethylene glycol, vegetable oil such as olive oil, or injectable esters such as ethyl oleate. Bases for suppository may be witepsol, macrogol, Tween 61, cacao butter, Laurin, or glycerogelatine.
In the pharmaceutical composition according to the present invention, a dose of rebamipide may vary depending on patient's state or body weight, seriousness of disease, dosage forms, administration routes, and the period of administration, and can be appropriately determined by a person having ordinary skill in the art. For example, 3o rebamipide may be administered in a dose of 0.1 to 100 mg/kg, preferably 0.5 to 50 mg/kg, more preferably 0.6 to 6 mg/kg, per day. Therefore, the pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.
The administration can be completed once or through several times per day. The pharmaceutical composition of the present invention can be also administered independently or in combination with other therapeutic agent(s) for osteoarthritis such as non-steroidal anti-inflammatory drugs (NSAIDs), etc. When administered as a combination, the therapeutic agent(s) can be administered sequentially or at the same time.
Hereinafter, the present invention will be described more specifically by the 1o following working example. However, the following working example is provided only for illustrations and thus the present invention is not limited to or by it.
Example: Evaluation of therapeutic efficacy of rebamipide on osteoarthritis according to oral administration (1) Test method About 5 week old male Wistar rats were used. Monosodium iodoacetate (MIA) was dissolved in a physiological saline; and then administered to the rats in the dose of 4 mg / 50 pl via the right knee thereof, so as to induce osteoarthritis.
The rats were divided into 3 groups, each having 5 rats. The first group (non-arthritis) was a non-treated group, i.e., a normal control group. The second group (MIA) was an osteoarthritis-induced group through the MIA administration. The rats of the third group (MIA+Rebamipide) were administered with the MIA to induce osteoarthritis; and then orally administered with rebamipide every day for 7 days.
At the 7th day after the MIA induction, the femurs and the tibias were isolated from the rats of each group and then observed under a dissecting microscope.
After H&E staining, the knee joint sites were observed through a low-magnification lens. In the results, the nucleus is shown in blue-violet color and the cytoplasm is shown in pink color. After completion of the stainings, the tissues were observed in detail, dividing two sites, i.e., the upper site of the knee (shown as "F" which is the abbreviation of femurs) and the lower site of the knee (shown as "T" which is the abbreviation of tibias).
The knee joints were stained with Safranin 0, which can show losses of the cartilage proteoglycans. The tartrate-resistant acid phosphatase (TRAP) staining for osteoclasts, was performed at 37 C for 30 minutes, using a leukocyte acid phosphatase kit (Sigma 387-A, USA). The TRAP-positive cells were shown in red-violet color. The multinucleated cells (having above 3 nuclei) were considered as TRAP-positive cells (osteoclasts), which were counted under an optical microscope.
(2) Test Results As a result of the observation of the femurs and tibias isolated from the rats of io each group under a dissecting microscope at the 7th day after the MIA
induction, the group not administered with rebamipide showed damages in the cartilage sites (see the red arrows of the middle pictures in FIG. 1). However, the group orally administered with rebamipide showed little damages in the cartilage sites (see FIG. 1).
And, as a result of histological analyses through TRAP, safranin 0, and H&E
staining, the group not administered with rebamipide showed serious cartilage damages, while the cartilage was remained intact without destruction in the group orally administered with rebamipide (see FIG. 2). That is, as a result of histological analysis through the H&E staining, it was observed that the inflammation in the group orally administered with rebamipide (MIA+Rebamipide) was favorably changed, in comparison with the MIA group. And also, as a result of analysis through the safranin 0 staining, it was observed in the group orally administered with rebamipide (MIA+Rebamipide) that the surface of the femoral cartilage site was smooth and shown in strong orange-red color, the results of which were similar to the non-arthritis group. In contrast, it was observed in the MIA group that the entire cartilage was weekly stained due to the proteoglycan losses and that the surface thereof became coarse. In addition, as a result of counting the number of osteoclasts in the tibial subchondral bone via TRAP
staining, the number of osteoclasts was significantly reduced in the group administered with rebamipide, in comparison with the MIA group.
And also, the histology grades were evaluated by scoring based on the standards of Table 1 below; and the results thereof were shown in FIG. 3. As shown in FIG. 3, the MIA group showed reduction in safranin 0 staining and irregular cartilage surface. However, it was observed in the rebamipide-treated group that the cartilage surface was remained smooth, showing only a little loss of safranin 0 in the cartilage site.
<Table 1 >
Symptom Histology grade Normal 1 Slight superficial reduction of safranin 0 staining 2 Reduction of safranin 0 staining and slight surface irregularity 3 Severe surface irregularity and/or clefts 4 Full non-calcified cartilage thickness loss 5 Calcified cartilage loss 6 The above results suggest that rebamipide inhibits cartilage damages, thereby exhibiting an excellent preventive and therapeutic activity against osteoarthritis.
(2) Test Results As a result of the observation of the femurs and tibias isolated from the rats of io each group under a dissecting microscope at the 7th day after the MIA
induction, the group not administered with rebamipide showed damages in the cartilage sites (see the red arrows of the middle pictures in FIG. 1). However, the group orally administered with rebamipide showed little damages in the cartilage sites (see FIG. 1).
And, as a result of histological analyses through TRAP, safranin 0, and H&E
staining, the group not administered with rebamipide showed serious cartilage damages, while the cartilage was remained intact without destruction in the group orally administered with rebamipide (see FIG. 2). That is, as a result of histological analysis through the H&E staining, it was observed that the inflammation in the group orally administered with rebamipide (MIA+Rebamipide) was favorably changed, in comparison with the MIA group. And also, as a result of analysis through the safranin 0 staining, it was observed in the group orally administered with rebamipide (MIA+Rebamipide) that the surface of the femoral cartilage site was smooth and shown in strong orange-red color, the results of which were similar to the non-arthritis group. In contrast, it was observed in the MIA group that the entire cartilage was weekly stained due to the proteoglycan losses and that the surface thereof became coarse. In addition, as a result of counting the number of osteoclasts in the tibial subchondral bone via TRAP
staining, the number of osteoclasts was significantly reduced in the group administered with rebamipide, in comparison with the MIA group.
And also, the histology grades were evaluated by scoring based on the standards of Table 1 below; and the results thereof were shown in FIG. 3. As shown in FIG. 3, the MIA group showed reduction in safranin 0 staining and irregular cartilage surface. However, it was observed in the rebamipide-treated group that the cartilage surface was remained smooth, showing only a little loss of safranin 0 in the cartilage site.
<Table 1 >
Symptom Histology grade Normal 1 Slight superficial reduction of safranin 0 staining 2 Reduction of safranin 0 staining and slight surface irregularity 3 Severe surface irregularity and/or clefts 4 Full non-calcified cartilage thickness loss 5 Calcified cartilage loss 6 The above results suggest that rebamipide inhibits cartilage damages, thereby exhibiting an excellent preventive and therapeutic activity against osteoarthritis.
Claims (5)
1. A pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is for oral administration.
3. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is in an oral solid dosage form of a tablet or capsule form.
4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.6 to 6 mg/kg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0019671 | 2010-03-05 | ||
| KR1020100019671A KR101182114B1 (en) | 2010-03-05 | 2010-03-05 | Pharmaceutical composition for preventing or treating osteoarthritis comprising rebamipide as active ingredient |
| PCT/KR2011/001497 WO2011108882A2 (en) | 2010-03-05 | 2011-03-04 | Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2791526A1 true CA2791526A1 (en) | 2011-09-09 |
Family
ID=44542738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2791526A Abandoned CA2791526A1 (en) | 2010-03-05 | 2011-03-04 | Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9301954B2 (en) |
| EP (1) | EP2543374B1 (en) |
| JP (1) | JP5769319B2 (en) |
| KR (1) | KR101182114B1 (en) |
| CN (1) | CN102791272A (en) |
| BR (1) | BR112012020415A2 (en) |
| CA (1) | CA2791526A1 (en) |
| ES (1) | ES2501047T3 (en) |
| RU (1) | RU2545768C2 (en) |
| WO (1) | WO2011108882A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2865669A4 (en) * | 2012-06-26 | 2015-12-02 | Samjin Pharm Co Ltd | Novel rebamipide prodrug, method for producing same, and usage thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101395984B1 (en) * | 2011-10-21 | 2014-05-16 | 가톨릭대학교 산학협력단 | Composition for preventing or treating obesity comprising rebamipide |
| WO2016108319A1 (en) * | 2015-01-02 | 2016-07-07 | 삼진제약 주식회사 | Novel rebamipide prodrug salt and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU683697B2 (en) * | 1993-10-21 | 1997-11-20 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivative for inhibiting production of interleukin-8 |
| WO1998010057A1 (en) * | 1996-09-06 | 1998-03-12 | Emory University | Methods for testing compounds for use as therapeutic antioxidants |
| AR015426A1 (en) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | BENZOTIAZOL COMPOUNDS ANTAGONISTS OF THE IL-8 RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE FOR PREPARATION, INTERMEDIARY COMPOUNDS AND PROCEDURE FOR PREPARATION |
| US8883761B2 (en) * | 2001-01-10 | 2014-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases associated with vasculature |
| JP4310605B2 (en) * | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | Pharmaceutical composition |
| EP1605916A4 (en) * | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | Solvent system of hardly soluble drug with improved elution rate |
| KR100612070B1 (en) * | 2003-02-12 | 2006-08-11 | 알앤피코리아주식회사 | Solvent system of hardly soluble drug with improved dissolution rate and pharmaceutical preparations containing the same |
| US7482356B2 (en) * | 2003-11-10 | 2009-01-27 | The Procter & Gamble Company | Bicyclic pyrazolone cytokine inhibitors |
| KR101104634B1 (en) * | 2009-08-25 | 2012-01-12 | 한림제약(주) | Pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide |
-
2010
- 2010-03-05 KR KR1020100019671A patent/KR101182114B1/en active IP Right Grant
-
2011
- 2011-03-04 CN CN2011800124634A patent/CN102791272A/en active Pending
- 2011-03-04 WO PCT/KR2011/001497 patent/WO2011108882A2/en active Application Filing
- 2011-03-04 US US13/582,929 patent/US9301954B2/en not_active Expired - Fee Related
- 2011-03-04 ES ES11750939.8T patent/ES2501047T3/en active Active
- 2011-03-04 JP JP2012556024A patent/JP5769319B2/en not_active Expired - Fee Related
- 2011-03-04 BR BR112012020415A patent/BR112012020415A2/en not_active Application Discontinuation
- 2011-03-04 EP EP11750939.8A patent/EP2543374B1/en not_active Not-in-force
- 2011-03-04 RU RU2012136190/15A patent/RU2545768C2/en not_active IP Right Cessation
- 2011-03-04 CA CA2791526A patent/CA2791526A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2865669A4 (en) * | 2012-06-26 | 2015-12-02 | Samjin Pharm Co Ltd | Novel rebamipide prodrug, method for producing same, and usage thereof |
| RU2612509C2 (en) * | 2012-06-26 | 2017-03-09 | Самджин Фармасьютикал Ко., Лтд. | New rebamipide prodrugs, method for their preparation and application |
| US11420963B2 (en) | 2012-06-26 | 2022-08-23 | Samjin Pharmaceutical Co., Ltd. | Rebamipide prodrugs, preparation method and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012020415A2 (en) | 2016-05-17 |
| EP2543374A4 (en) | 2013-07-10 |
| US9301954B2 (en) | 2016-04-05 |
| JP2013521277A (en) | 2013-06-10 |
| RU2012136190A (en) | 2014-04-10 |
| WO2011108882A2 (en) | 2011-09-09 |
| EP2543374B1 (en) | 2014-07-09 |
| JP5769319B2 (en) | 2015-08-26 |
| KR20110100700A (en) | 2011-09-15 |
| WO2011108882A3 (en) | 2012-01-12 |
| CN102791272A (en) | 2012-11-21 |
| US20130065920A1 (en) | 2013-03-14 |
| KR101182114B1 (en) | 2012-09-12 |
| ES2501047T3 (en) | 2014-10-01 |
| EP2543374A2 (en) | 2013-01-09 |
| RU2545768C2 (en) | 2015-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2739266B1 (en) | Stable anti-inflammatory solutions for injection | |
| EP2543374B1 (en) | Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient | |
| CA2770778C (en) | Pharmaceutical composition for preventing or treating rheumatoid arthritis containing rebamipide | |
| Trevisan et al. | Bone loss and recovery in regional migratory osteoporosis | |
| RU2691946C2 (en) | Scheme for using fgf-18 compound | |
| US20170266168A1 (en) | Methods for preventing or treating osteoarthritis | |
| JP2023071181A (en) | Methods for inducing chondrogenesis | |
| JPH03151328A (en) | Pharmaceutical agent for degenerating or stabilizing atherosclerosis of coronary arteries | |
| MXPA04001868A (en) | Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration. | |
| EP3865472A1 (en) | Thromboxane receptor antagonists | |
| KR102034310B1 (en) | Pharmaceutical composition for prevention or treatment of inflammatory diseases containing integrin inhibitor as an active ingredient | |
| AU2008328311B2 (en) | Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof | |
| KR102167998B1 (en) | Composition for prevention or treatment of osteoarthritis comprising jeju magma seawater | |
| JPWO2006088088A1 (en) | Pain treatment agent containing ROCK inhibitor | |
| Mullaji et al. | Computer-assisted TKA: greater precision, doubtful clinical efficacy: opposes | |
| KR101771222B1 (en) | Pharmaceutical composition for prevention or treatment of inflammatory diseases containing integrin inhibitor as an active ingredient | |
| KR102375161B1 (en) | A combination pharmaceutical composition for treating fibrotic diseases | |
| KR102315866B1 (en) | A development of combination therapy for fibrotic diseases | |
| Abd-el-Moneim et al. | The Therapeutic Potential of Ginger and/or Glucosamine Sulfate on Adjuvant-Induced Rheumatoid Arthritis in Adult Rats; an Anatomical, Histological and Biochemical Study | |
| CA2498049A1 (en) | At<sb>1</sb> receptor antagonists for preventing secondary strokes | |
| JP2007153891A (en) | Medicine for suppressing chronic progressive renal disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20170306 |